Actinium Pharmaceuticals, Inc. ATNM
1.64 USD +0.05 (+3.14%)
At closeNov 13, 2026, 4:31 PM EST
1.66 +0.02 +1.22%
After hours · Nov 13, 4:31 PM ET
1.56 Day range 1.64
0.749 52-week range 1.69
- YTD
- +20.59%
- 1 year
- +31.20%
News
prnewswire.com Actinium Pharmaceuticals to Host KOL Webinar on ATNM-400, a First-in-Class HER3-Targeted Alpha Radiotherapy Leading prostate cancer expert Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, to discuss unmet needs in metastatic castration-resistant prostate cancer (mCRPC) and the potential…
prnewswire.com Actinium Pharmaceuticals Announces Enrollment in the RADIANZ Imaging Clinical Trial Intended to Demonstrate the Pan-Cancer Potential of ATNM-400, A First-in-Class HER3-Targeting Radiotherapy RADIANZ results will inform ATNM-400 clinical development beyond prostate cancer to patients with advanced HER3-expressing solid tumors in multiple cancers Builds on initial first-in-human clinical…
prnewswire.com Actinium Pharmaceuticals Announces Formation of Scientific Advisory Board Featuring Leading Experts in Oncology and Radiopharmaceutical Development Scientific Advisory Board brings together world-class expertise in prostate cancer, hematologic malignancies, molecular imaging, radiochemistry and clinical development Internationally recognized…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Axogen (NASDAQ:AXGN) stock rose 17.7% to $44.1 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q3 earnings report…
benzinga.com Actinium Pharma To Present First‑In‑Human Phase 1 Study Of ATNM‑400, HER3-Targeted, Non-PSMA Radiotherapy, In Metastatic Castration‑Resistant Prostate Cancer, At ESMO Congress 2026 First‑in‑human Phase 1 study evaluates HER3‑targeted ATNM‑400 in metastatic castration‑resistant prostate cancer population, including patients with and without prior PSMA‑directed therapy…
benzinga.com Why Is Actinium Pharmaceuticals Stock Gaining Tuesday? Actinium Pharmaceuticals shares jump 9% after positive Phase 1 ATNM-400 trial results in prostate cancer show early safety and retention.
benzinga.com Actinium Pharmaceuticals Presents New Preclinical Data From Its ATNM-400 Across Non-Small Cell Lung Cancer At 39th Annual Congress Of European Association Of Nuclear Medicine Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced new…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Silence Therapeutics (NASDAQ:SLN) stock increased by 125.6% to $19.59 during Monday's regular session. The market value of their outstanding shares is at $581.1 million. SCWorx (NASDAQ:WORX)…
benzinga.com Actinium Pharmaceuticals To Present Data And Preclinical Results For ANTM-400 At The Congress Of The European Association Of Nuclear Medicine, October 17–21 First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMAPreclinical presentation to…- benzinga.com Actinium Pharma To Present Preclinical Data Supporting ATNM-400's Broad Potential At 39th Annual Congress Of EANM Oral presentation to highlight ATNM-400 antitumor activity across KRAS- and ALK-driven NSCLC models, building on earlier EGFR-mutant findings and supporting mutation-agnostic development Colorectal…
benzinga.com Actinium Pharmaceuticals To Present Early Phase 1 Clinical Data For ATNM-400 In Metastatic Prostate Cancer At EANM 2026 Early clinical data from the Phase 1 theranostic trial support the advancement of ATNM-400 as a non-PSMA targeted alpha therapy for metastatic castration-resistant prostate cancer (mCRPC) Evaluation…- benzinga.com Actinium Pharmaceuticals Appoints Dr. Matt David As CFO Dr. David brings more than two decades of experience across biopharmaceutical operating leadership, healthcare investment banking and equity research. He joins Actinium from CorMedix Inc.…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…- benzinga.com Actinium Pharmaceuticals Advances Actimab-A Program With New Patents, Expanded Manufacturing Capacity And Clinical Milestones Into 2027 Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced advances across its Actimab-A program, including…
benzinga.com Actinium Pharmaceuticals Receives NYSE American Compliance Plan Acceptance, Granted Until Nov. 27, 2027 To Regain Listing Compliance American LLC ("NYSE American") that the Company was not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide (the "Company
benzinga.com Actinium Pharmaceuticals Q2 EPS $0.89 Beats $(0.21) Estimate, Sales $35.000M Actinium Pharmaceuticals (AMEX:ATNM) reported quarterly earnings of $0.89 per share which beat the analyst consensus estimate of $(0.21) by 523.81 percent. This is a 504.55 percent increase over…- benzinga.com Actinium's ATNM-400 Reports Preclinical Activity And Combination Synergy Across KRAS- And EGFR-Mutant NSCLC, Supporting Mutation-Agnostic Potential New KRAS-mutant data show ATNM-400 outperformed standard-of-care inhibitors sotorasib and adagrasib as a monotherapy. Treatment with these agents increased expression of the ATNM-400 target greater…
benzinga.com Actinium Pharma Presents New Data On ATNM-400 In Prostate Cancer At SNMMI 2026 Annual Meeting New data demonstrated ATNM-400 remains potently active in prostate cancer cells and tumors resistant to all three approved androgen receptor inhibitors (ARPIs) -enzalutamide (Xtandi®), apalutamide…- benzinga.com Actinium Pharmaceuticals Obtains Two Patent Allowances Spanning Its Actimab-A And Iomab-ACT Programs Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that the Canadian Intellectual Property Office (CIPO) has…
benzinga.com Actinium Pharmaceuticals To Reveal ATNM-400 Program Update At SNMMI 2026 Conference on May 31-June 2; Co. Receives NYSE Noncompliance Notice Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced it will provide a program update on its first-in-class…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 369 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 445 companies made new 52-week lows.
benzinga.com Stocks That Hit 52-Week Highs On Monday This morning 180 companies set new 52-week highs.- benzinga.com 81 Biggest Movers From Yesterday Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares climbed 112.5% to close at $7.80 on Monday after gaining around 6% on Friday.
- benzinga.com 64 Stocks Moving In Monday's Mid-Day Session Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 218% to $11.67 after gaining around 6% on Friday.
- benzinga.com 31 Stocks Moving in Monday's Pre-Market Session Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares rose 184% to $10.41 in pre-market trading after gaining around 6% on Friday.
- benzinga.com 81 Biggest Movers From Yesterday Gainers Electrameccanica Vehicles Corp. (NASDAQ: SOLO) climbed 64.5% to close at $5.15 on Monday after jumping more than 34% on Thursday.
- benzinga.com 60 Stocks Moving In Thursday's Mid-Day Session Gainers Cinedigm Corp. (NASDAQ: CIDM) shares jumped 201.5% to $3.95 after the company announced it has partnered with Vewd for global OTT channel distribution. On Wednesday, Cinedigm reported the…
- benzinga.com Stocks That Hit 52-Week Lows On Monday
- benzinga.com 38 Biggest Movers From Yesterday
- benzinga.com 28 Stocks Moving In Monday's Mid-Day Session